Goldman Sachs Maintains Buy on Intellia Therapeutics, Raises Price Target to $252
Goldman Sachs maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $225 to $252.
10 Biggest Price Target Changes For Friday
Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading.
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $177
Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $130 to $177.
Why Intellia Therapeutics’ Stock Is Trading Higher Today
Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Thursday after the company announced its second-quarter financial results and said it plans to initiate Phase 1 trials for its next two candidates later this year.
Intellia Therapeutics Q2 EPS $(1.01) Misses $(0.63) Estimate, Sales $6.55M Miss $11.89M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.63) by 60.32 percent. This is a 65.57 percent decrease over losses of $(0.61) per
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.